Plain-English translation of NCT05833763 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications called and in people with mantle cell lymphoma (a type of blood cancer) that has returned or stopped responding to previous treatments. The researchers want to see if using these two medications together works better than either one alone, and whether the combination is safe and can help patients achieve remission.
Many patients with mantle cell lymphoma eventually develop resistance to BTK inhibitors, a class of drugs commonly used to treat this cancer. This trial exists to find a new treatment option for these patients whose cancer has become harder to control.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of one of the medications on a set schedule over several weeks, with gradually increasing doses during the first phase to check for side effects. After the initial ramp-up period, you would continue with the full dose combination for about 10 more cycles (each cycle is 21 days), then switch to an oral tablet taken daily at home for ongoing maintenance. Throughout the trial, you would have regular clinic visits for blood tests, scans, and check-ins to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Australia